/ Print /

IN THE PIPELINE

FDA issues new warning on liver disease drugFDA is adding a Boxed Warning, its most prominent warning, on a liver disease medicine.
Combo UTI drug can now treat costly pneumoniasFDA approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of ceftazidime and avibactam (Avycaz) to include 2 types of pneumonia.
Single-use MIGS device demonstrates significant reduction in IOP in retrospective studyTrabecular bypass procedures have become a viable option for glaucoma treatment. The Kahook Dual Blade (KDB) facilitates ab interno trabeculectomy by employing a single-use, micro-engineered excision blade that makes precise parallel incisions in the trabecular meshwork and inner wall of the Schlemm’s canal to enhance aqueous outflow. A recent study highlights the effectiveness of its application.
Cataract surgery may raise diabetic macular oedema riskCataract surgery increases the risk of diabetic macular oedema (DMO), medical records from the United Kingdom suggest. An analysis of 4,850 eyes showed that the rate of DMO requiring treatment spiked about 4 months after the surgery.
Radioactive drug for digestive cancer snags FDA approvalFDA approved a new drug to treat a type of cancer that affects the pancreas or gastrointestinal tract.
Cannabis-derived epilepsy drug on the horizonA pharmaceutical formulation of purified cannabidiol, a cannabinoid without euphoric side effects, is expected to launch in the second half of this year.
Low-dose ranibizumab effective for retinopathy of prematurityA low dose of ranibizumab (Lucentis, Genentech/Roche) works well as a treatment for retinopathy of prematurity (ROP), researchers say.
Blindness gene therapy price tag stirs controversyA patient advocacy group is criticizing the hefty price tag of a new treatment for blindness.
Survey uncovers lupus corticosteroid treatment issuesPatients with systemic lupus erythematosus often self-manage their corticosteroid medication without the consent of their healthcare providers, according to a recent multicountry survey.
FDA takes tough stance on kids’ opioid cold medsFDA is taking its toughest stance yet on opioid-containing cough and cold medications for children.